PCVX Q3 2022 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$59M

Net Income

-$58M

EPS (Diluted)

$-0.93

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$412M

Total Liabilities

$53M

Stockholders' Equity

$359M

Cash & Equivalents

$278M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$59M	-$27M	-117.3%
Net Income	-$58M	-$27M	-117.6%